18 matches for your search in the start-up spotlight
rss
Lasso is transforming our food system with a breakthrough technology that converts simple ingredients into premium food products. Developed by Harvard scientists at the Wyss Institute, Lasso’s innovative technology “spins” fibers, leveraging centrifugal force to restructure simple ingredients ...
Neoclease is a biotechnology company pioneering AI-designed gene-editing therapies optimized for individual genes. Using a proprietary platform that integrates generative protein models with synthetic biology, Neoclease builds ultra-precise, delivery-ready nucleases for diseases with high unmet ...
Breaking is a plastic degradation company gestated at Colossal Biosciences that uses synthetic biology. Its flagship product, X-32 was discovered in 2022 at the Wyss Institute at Harvard University. Co-founded by Sukanya Punthambaker, Vaskar Gnyawali, George Church, Don Ingber, Alba Tull, Kent ...
Breaking is a plastic degradation company gestated at Colossal Biosciences that uses synthetic biology. Its flagship product, X-32 was discovered in 2022 at the Wyss Institute at Harvard University. Co-founded by Sukanya Punthambaker, Vaskar Gnyawali, George Church, Don Ingber, Alba Tull, Kent ...
Dewpoint is the first company to apply the emerging understanding of biomolecular condensates to drug discovery for the vast range of conditions that are regulated by condensates or arise from the dysfunction of condensates. Dewpoint currently has programs across an ambitious pipeline spanning ...
TransCode is an RNA oncology company created on the belief that cancer can be effectively treated using RNA therapeutics. The Company has created a platform of drug candidates designed to target a variety of tumor types with the objective of significantly improving patient outcomes. The Company’s ...
At IFM Therapeutics, we are transforming immunotherapy to improve the lives of patients with serious diseases. We focus on developing small molecule drugs that precisely target the innate immune system, the body’s first line of immunological response. The majority of advances in immunotherapy ...
Kojin Therapeutics is the first biopharmaceutical company using a proprietary approach to cell state and ferroptosis biology to develop novel, targeted therapeutics for diseases of high unmet need. Founded by Stuart Schreiber, Benjamin Cravatt, Stephanie Dougan and Vasanthi Viswanathan, Kojin is ...
